ClinicalTrials.gg
CompletedNCT00615433Updated Jun 12, 2015Results posted

Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia

A Phase 3 interventional study of Lurasidone and Olanzapine in Schizophrenia, sponsored by Sumitomo Pharma America, Inc.. Completed at 52 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-06-12.

Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
478
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 39 studies testing lurasidone in Schizophrenia — none open to participants now, none under way, none of them phase 3. lurasidone · Schizophrenia.

Enrollment
6th of 39
478 · median 149
Started
2008
with 8 others
Phase 3
18 of 39
none open now
Registered
6th of 39
by date
Lead sponsor
23 of 39
Sumitomo Pharma America, Inc.

Among the 39 studies testing lurasidone in Schizophrenia, this one is the 6th largest by enrollment, is one of 9 that started in 2008, is one of 18 in phase 3, and was the 6th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 39 studies testing lurasidone in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →

About lurasidone

lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing lurasidone in Schizophrenia as a file.
02

Study summary

Lurasidone HCl is a compound developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is more efficacious than placebo. The study will also evaluate the safety and tolerability of lurasidone as compared to placebo.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • Latuda
  • Lurasidone
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide written and aged between 18 and 75 years of age.
  • Meets criteria for a primary diagnosis of schizophrenia.
  • Not pregnant, if of agrees to remain abstinent or use adequate and reliable for duration of study.
  • Able and agrees to remain off prior antipsychotic medication for the duration of study.
  • Good physical health on the basis of medical history, physical examination, and laboratory screening.
  • Willing and able to comply with the protocol, including the inpatient requirements and outpatient visits.

Exclusion criteria

Exclusion Criteria:

  • Considered by the investigator to be at imminent risk of suicide or injury to self, others or property.
  • Any chronic organic disease of the CNS (other than schizophrenia).
  • Used compound within 30 days.
  • or history of alcohol abuse/alcoholism or drug abuse/dependence within the last 6 months
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
478 participants (actual)

Study arms

  • Experimental
    Lurasdione 40mg tablets

    Drug: Lurasidone 40 mg tablets

  • Experimental
    120mg

    Drug: Lurasidone

  • Active comparator
    15mg Olz

    Drug: Olanzapine

  • Placebo comparator
    Sugar pill

    Drug: Placebo comparator

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Total PANSS (Positive and Negative Syndrome Scale)Score From Baseline to the End of the Double Blind Treatment Period.

    The PANSS is a 30-item rating instrument evaluating the presence/absence and severity of positive, negative and general psychopathology of schizophrenia. The scale was developed from the BPRS and the Psychopathology Rating Scale. All 30 items are rated on a 7-point scale (1=absent; 7=extreme). The total score can range from 30 to 210. Lower scores represent less severity of illness.

    Time frame: Baseline and 6 weeks

Secondary outcomes

  1. CGI-S (Clinical Global Impression - Severity) Change From Baseline to the End of the Double-blind Treatment.

    The CGI-S is a clinician-rated assessment of the subject's current illness state on a 7-point scale, where a higher score is associated with greater illness severity.

    Time frame: 6 weeks

07

Results

Posted Feb 14, 2011

Participant flow

Participant flow — Overall Study
Milestone40mg120mg15mg OlzPlacebo
Started120119123116
Completed77668471
Not completed43533945

Outcome measures

PrimaryChange in Total PANSS (Positive and Negative Syndrome Scale)Score From Baseline to the End of the Double Blind Treatment Period.

The PANSS is a 30-item rating instrument evaluating the presence/absence and severity of positive, negative and general psychopathology of schizophrenia. The scale was developed from the BPRS and the Psychopathology Rating Scale. All 30 items are rated on a 7-point scale (1=absent; 7=extreme). The total score can range from 30 to 210. Lower scores represent less severity of illness.

Time frame:
Baseline and 6 weeks
Reported as:
Least squares mean · Units on a scale
Change in Total PANSS (Positive and Negative Syndrome Scale)Score From Baseline to the End of the Double Blind Treatment Period.
Units on a scale40mg120mg15mg OlzPlacebo
Change in Total PANSS (Positive and Negative Syndrome Scale)Score From Baseline to the End of the Double Blind Treatment Period.-25.7 (-29.6 to -21.8)-23.6 (-27.8 to -19.4)-28.7 (-32.4 to -24.9)-16.0 (-20.1 to -12.0)
Statistical analysis
  • 40mg vs 120mg vs Placebo · Mixed Models Analysis · p = <0.05
SecondaryCGI-S (Clinical Global Impression - Severity) Change From Baseline to the End of the Double-blind Treatment.

The CGI-S is a clinician-rated assessment of the subject's current illness state on a 7-point scale, where a higher score is associated with greater illness severity.

Time frame:
6 weeks
Reported as:
Least squares mean · scale
CGI-S (Clinical Global Impression - Severity) Change From Baseline to the End of the Double-blind Treatment.
scale40mg120mg15mg OlzPlacebo
CGI-S (Clinical Global Impression - Severity) Change From Baseline to the End of the Double-blind Treatment.-1.5 (-1.7 to -1.3)-1.4 (-1.6 to -1.2)-1.5 (-1.7 to -1.4)-1.1 (-1.3 to -0.9)
Statistical analysis
  • 40mg vs 120mg vs Placebo · Mixed Models Analysis · p = <0.05

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
40mg—2/119 (1.7%)90/119 (75.6%)
120mg—6/118 (5.1%)96/118 (81.4%)
15mg Olz—5/122 (4.1%)98/122 (80.3%)
Placebo—5/116 (4.3%)84/116 (72.4%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
Event40mg120mg15mg OlzPlacebo
Psychotic DisorderPsychiatric disorders0/1194/1181/1221/116
SchizophreniaPsychiatric disorders1/1192/1181/1220/116
Acute Myocardial InfarctionCardiac disorders0/1190/1180/1221/116
Angina PectorisCardiac disorders0/1190/1180/1221/116
HeamatemesisGastrointestinal disorders0/1190/1180/1221/116
AgitationPsychiatric disorders1/1190/1180/1221/116
Panic AttackPsychiatric disorders0/1190/1180/1221/116
Suicidal IdeationPsychiatric disorders1/1191/1181/1220/116
Substance AbusePsychiatric disorders1/1190/1180/1220/116
Sinus TachycardiaCardiac disorders0/1190/1181/1220/116
Most frequent other events
Showing 10 of 25
Most frequent other events
Event40mg120mg15mg OlzPlacebo
AkathisiaNervous system disorders14/11927/1189/1221/116
HeadacheNervous system disorders26/11921/11817/12225/116
Weight IncreasedInvestigations2/1192/11825/1226/116
SomnolenceNervous system disorders11/11918/11811/1225/116
SedationNervous system disorders11/11916/11817/1224/116
InsomniaPsychiatric disorders15/11914/11813/12213/116
ParkinsonismNervous system disorders11/11913/1186/1222/116
NauseaGastrointestinal disorders13/1199/1186/1225/116
AgitationPsychiatric disorders13/1197/1188/1226/116
AnxietyPsychiatric disorders12/11912/1187/1228/116

Baseline characteristics

Age, Continuous
Age, Continuous(years)40mg120mg15mg OlzPlaceboTotal
Mean37.7 ± 11.037.9 ± 11.238.3 ± 10.236.9 ± 11.337.7 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)40mg120mg15mg OlzPlaceboTotal
Female26252726104
Male93939590371
Region of Enrollment
Region of Enrollment(participants)40mg120mg15mg OlzPlaceboTotal
United States70727468284
Philippines768526
Lithuania777829
Colombia1212121248
India2321212388
08

Study locations

52 sites
  • K&S Professional Research Services LLC
    Little Rock, Arkansas 72201, United States
  • Woodland International Research Group, LLC
    Little Rock, Arkansas 72211, United States
  • Clinical Pharmacological Studies, Inc.
    Cerritos, California 90703, United States
  • Excell Research
    Oceanside, California 92056, United States
  • University of California at Irvine Medical Center
    Orange, California 92868, United States
  • California Clinical Trials
    Paramount, California 90723, United States
  • CNRI - San Diego, LLC
    San Diego, California 92102, United States
  • UCSD Medical Center
    San Diego, California 92103, United States
  • Collaborative Neuroscience Network Inc.
    Torrance, California 90502, United States
  • Florida Clinical Research Center, LLC
    Fruitland Park, Florida 24731, United States
  • Segal Institute for Clinical Research
    North Miami, Florida 33161, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30308, United States
  • Uptown Research Institute, LLC
    Chicago, Illinois 60640, United States
  • Alexian Brothers Health System
    Hoffman Estates, Illinois 60169, United States
  • Lousiana Clinical Research, LLC
    Shreveport, Louisiana 71104, United States
  • Precise Research Center
    Flowood, Mississippi 39232, United States
  • St. Charles Psychiatric Associates-Midwest Research
    St. Charles, Missouri 63301, United States
  • St. Louis Clinical Trials
    St. Louis, Missouri 63118, United States
  • CRI Worldwide @ Lourdes
    Willingboro, New Jersey 08046, United States
  • Neurobehavioral Research Inc.
    Cedarhurst, New York 11516, United States
  • University of North Carolina at Chapel Hill
    Raleigh, North Carolina 27603, United States
  • Keystone Clinical Studies, LLC
    Norristown, Pennsylvania 19401, United States
  • Vanderbilt Heart and Vascular Institute
    Nashville, Tennessee 37212, United States
  • Community Clinical Research, Inc.
    Austin, Texas 78754, United States
  • Claghorn-Lesem Research Clinic, Inc.
    Houston, Texas 77008, United States
  • Instituto Colombiano del Sistema Nervioso Clinica Montserrat
    Cundinamarca, Bogota, Colombia
  • CIPNA Centro de Investigaciones y Proyectos en Neurociencias
    Barranquilla, Colombia
  • Centro de Investigacion y Atencion para la Salud Mental
    Bogota, Colombia
  • Centro de Investigaciones del Sistema Nervioso Limitada
    Bogota, Colombia
  • Psynapsis Salud Mental, S.A.
    Risaralda, Colombia
  • Vijayawada Institute of Mental Health and Neurosciences
    Vijaywada, Andh Prad 520002, India
  • Government Hospital for Mental Care
    Visakhapatnam, Andh Prad 530017, India
  • Hospital for Mental Health - Dept of Psychiatry
    Ahmedabad, Gujarat 380004, India
  • Sheth Vadilal Sarabhai General Hospital
    Ahmedabad, Gujarat 380006, India
  • SBKS Medical College and Brij Psychiatry Hospital
    Vadodara, Gujarat 390001, India
  • Victoria Hospital
    Bangalore, Karna 56002, India
  • Kasturba Medical College
    Mangalore, Karna 575001, India
  • Father Muller Institute of Medical Education and Research
    Mangalore, Karna 575002, India
  • Justice K.S. Hedge Charitable Hospital
    Mangalore, Karna 575018, India
  • Kasturba Hospital
    Manipal, Karna 576104, India
  • JSS Medical College and Hospital - Dept of Psychiatry
    Mysore, Karna 570004, India
  • Shanti Nursing Home
    Aurangabad, Mahara 431005, India
  • Deenanath Mangeshkar Hospital
    Pune, Mahara 411004, India
  • Madras Medical College & Government General Hospital
    Chennai, TamilNadu 600003, India
  • Ziegzdriai Mental Hospital, Public Institution
    Kaunas, 53136, Lithuania
  • Klaipeda Mental Hospital, Public Institution
    Klaipeda, 91251, Lithuania
  • Siauliai Mental Hospital, Public Institution
    Siauliai, 76231, Lithuania
  • Republican Vilnius Psychiatry Hospital, Public Institution
    Vilnius, 11205, Lithuania
  • Davao Medical School Foundation Hospital
    Davao City, 8000, Philippines
  • Makati Medical Center
    Makati City, 1227, Philippines
  • National Center for Mental Health
    Mandaluyong City, 1553, Philippines
  • Metro Psych Facility
    Mandaue City, 6014, Philippines
09

References and documents

Publications

  • Meltzer HY, Cucchiaro J, Silva R, Ogasa M, Phillips D, Xu J, Kalali AH, Schweizer E, Pikalov A, Loebel A. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry. 2011 Sep;168(9):957-67. doi: 10.1176/appi.ajp.2011.10060907. Epub 2011 Jun 15. PubMed 21676992 ↗
  • Stahl SM, Cucchiaro J, Simonelli D, Hsu J, Pikalov A, Loebel A. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. J Clin Psychiatry. 2013 May;74(5):507-15. doi: 10.4088/JCP.12m08084. Epub 2013 Mar 13. PubMed 23541189 ↗
  • Hopkins SC, Ogirala A, Worden M, Koblan KS. Depicting Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS. Clin Drug Investig. 2021 Dec;41(12):1067-1073. doi: 10.1007/s40261-021-01094-7. Epub 2021 Nov 9. PubMed 34751928 ↗
  • Nasrallah HA, Cucchiaro JB, Mao Y, Pikalov AA, Loebel AD. Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies. CNS Spectr. 2015 Apr;20(2):140-7. doi: 10.1017/S1092852914000285. Epub 2014 Jun 23. PubMed 24955752 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Dec 2009 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2011, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2008
First posted
Feb 14, 2008
Start
Jan 2008
Primary completionActual
Dec 2009
CompletionActual
Jan 2010
Results first posted
Feb 14, 2011
Last update
Jun 12, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00615433
Responsible party
Sponsor
First posted
Feb 14, 2008
Start date
Jan 2008
Primary completion
Dec 2009
Completion
Jan 2010
Results posted
Feb 14, 2011
Last update
Jun 12, 2015

Study contacts

Medical Director, MD
study director · Sumitomo Pharma America, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lurasidone

Start the discussion